NEUROCRINE BIOSCIENCES INC NBIX

Latest FY: 2025 Healthcare Drug Manufacturers - Specialty & Generic
Market Price $156.53
Market Cap $15.74B
P/E Ratio 33.52
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑21.4% YoY
$2.86B
3-Yr CAGR: 24.3%
Net Income ↑40.2% YoY
$478.60M
Net Margin: 16.7%
Free Cash Flow ↑34.4% YoY
$748.70M
FCF Yield: 4.76%
EPS (Diluted) ↑41.9% YoY
$4.67
Basic: $4.81
Return on Equity Efficiency
14.7%
ROA: 10.3%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NBIX)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $15.0M $15.0M $-141.1M $-1.63 0.00% $-106.2M $-110.3M
FY 2017 $161.6M +977.5% $142.1M $-142.5M -1.0% $-1.62 +0.6% 0.00% $-94.3M $-101.3M +8.2%
FY 2018 $451.2M +179.2% $420.7M $21.1M +114.8% $0.22 +113.6% 0.00% $101.4M $76.6M +175.6%
FY 2019 $788.1M +74.6% $426.3M $37.0M +75.3% $0.39 +77.3% 0.00% $152.1M $137.3M +79.4%
FY 2020 $1,045.9M +32.7% $1,013.1M $407.3M +1,000.5% $4.16 +966.7% 0.00% $228.5M $217.6M +58.5%
FY 2021 $1,133.5M +8.4% $1,107.7M $89.6M -78.0% $0.92 -77.9% 0.00% $256.5M $233.1M +7.1%
FY 2022 $1,488.7M +31.3% $1,465.5M $154.5M +72.4% $1.56 +69.6% 0.00% $339.4M $322.9M +38.5%
FY 2023 $1,887.1M +26.8% $1,847.4M $249.7M +61.6% $2.47 +58.3% 0.00% $389.9M $361.6M +12.0%
FY 2024 $2,355.3M +24.8% $2,321.3M $341.3M +36.7% $3.29 +33.2% 0.00% $595.4M $557.2M +54.1%
FY 2025 $2,860.5M +21.4% $2,808.4M $478.6M +40.2% $4.67 +41.9% 0.00% $782.7M $748.7M +34.4%
$

Valuation

Market Price $156.53
Market Cap $15.74B
Enterprise Value $15.03B
P/E Ratio 33.52
P/B Ratio 4.84
FCF Yield 4.76%
Dividend Yield N/A
Shares Outstanding 100,550,000
%

Profitability & Margins

Gross Margin 98.18%
Operating Margin 21.64%
Net Margin 16.73%
Return on Equity (ROE) 14.71%
Return on Assets (ROA) 10.33%
Asset Turnover 0.62x
Revenue 3-Yr CAGR 24.32%
🛡️

Financial Health & Liquidity

Current Ratio 3.39
Cash Ratio 0.96
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents $713.00M
Total Debt N/A
Book Value / Share $32.35
💧

Cash Flow Efficiency

Operating Cash Flow $782.70M
Capital Expenditures (CapEx) $34.00M
Free Cash Flow $748.70M
OCF / Revenue 27.36%
FCF / Revenue 26.17%
FCF 3-Yr CAGR 32.36%
🏷️

Per Share Metrics

EPS (Diluted) $4.67
EPS (Basic) $4.81
Dividends / Share N/A
Book Value / Share $32.35
EPS YoY Growth 41.95%
🏛️

Balance Sheet (FY 2025)

Total Assets $4.63B
Total Liabilities $1.38B
Stockholders' Equity $3.25B
Current Assets $2.52B
Current Liabilities $743.40M